中药二黄散对宫颈炎症及宫颈上皮内瘤变治疗作用的初步探讨
|
摘要
第一部分武汉地区宫颈疾病分布情况的临床调查
目的了解武汉地区宫颈疾病的分布情况,为研究宫颈疾病的发病机制、诊治及预防提供临床资料。
方法对2004年12月至2005年5月在同济医院妇产科门诊就诊的2635例慢性宫颈炎患者行TCT检查和TBS细胞学分类诊断,对TCT检查发现异常的患者进行阴道镜病理检查和HC-ⅡHPV DNA检测。
结果2635例TCT涂片中检出异常涂片493例(18.71%) ,其中不典型鳞状细胞(ASCUS)271例(10.28%) ,低度鳞状上皮内病变(LSIL) 94例(3.57%) ,高度鳞状上皮内病变(HSIL) 14例( 0.53%),鳞状细胞癌(SCC) 1例(0.04% ) ,子宫内膜腺癌1例(0.04%)。阴道镜病检CINⅠ、CINⅡ、CINⅢ检出率分别为31.18% ( 53 /170 )、23.53% ( 40 /170 )、7.06% ( 12 /170 )。TCT示HPV感染共105例,行HPV-DNA检测其中高危型HPV阳性者74例,占70.48%。
结论宫颈疾病是育龄妇女的常见病,其中宫颈上皮不典型增生及高危型HPV感染是困扰女性生殖健康的主要元凶。
第二部分中药二黄散治疗CINⅠ,Ⅱ合并高危型HPV感染的临床观察及其对血清中IFN-γ,TNF-α,IL-4和IL-10的影响
目的:观察中药二黄散治疗CINⅠ,Ⅱ合并高危型HPV感染的临床疗效及其对血清中IFN-γ,TNF-α,IL-4和IL-10的影响。
方法:CINⅠ,Ⅱ合并高危型HPV感染158例,其中94例采用二黄散治疗3个月,30例采用α-2b干扰素栓进行对照治疗及34例空白对照,应用二代免疫杂交捕获技术(HC-Ⅱ)于治疗前后分别检查宫颈涂片中高危型HPV-DNA及阴道镜病理检查。抽取二黄散治疗组患者血液,用ELISA方法检测用中药二黄散治疗前后血液中IFN-γ,TNF-α,IL-4和IL-10变化情况。
结果:二黄散与α-2b干扰素栓对高危型HPV感染的治疗作用有效率分别为75.6%,73.3%。对于CINⅠ,Ⅱ的治疗有效率为72.4%及73.3%。二者作用相近但明显高于未用药治疗组。CINⅠ,Ⅱ合并高危型HPV感染患者用中药二黄散治疗后,IFN-γ,TNF-α升高而IL-4,IL-10下降。
结论:二黄散对于宫颈上皮内瘤变有一定治疗作用。二黄散能使高危型HPV感染者Th1类细胞因子升高,Th2类细胞因子降低,使细胞免疫占优势,从而有利于病毒的清除。
第三部分中药二黄散对大鼠子宫颈炎病理形态学的作用及对大鼠宫颈TNF-α,IL-10表达的影响
目的:探讨大鼠宫颈炎模型的建立方法,以有效建立宫颈炎模型,为基础及临床研究宫颈炎提供一种有用动物模型。评价中药二黄散对于大鼠宫颈炎病理形态学的作用,观察使用中药治疗前后大鼠宫颈局部TNF-α,IL-10表达的变化情况,初步探讨中药二黄散对大鼠宫颈免疫功能的影响作用。
方法:1.建立实验大鼠宫颈炎模型,将20%苯酚浆胶注入实验大鼠阴道内,1次/2日,共5次。2.造模成功后第2天,将造模组大鼠分3组,分别给予相当于成人用量30倍的二黄散,消糜栓(阳性对照)和空白基质(阴性对照),均隔日给药1次,共12次。此外,将未经任何处理的大鼠作为正常对照组。观察大鼠整体状况及阴道分泌物性状。治疗结束后次日处死动物,取子宫观察,宫颈常规石蜡切片行HE染色并在显微镜下观察宫颈形态学变化及炎症程度。3.分别采用免疫组织化学(S-P法),逆转录-聚合酶链反应(RT-PCR)检测中药二黄散用药前后大鼠宫颈TNF-α,IL-10蛋白和mRNA表达。
结果:1.病理检查结果:中药二黄散组和消糜栓组(阳性对照组)与阴性对照组相应部位比较,分泌物及炎症程度明显减轻,炎症细胞浸润明显减少,比较有显著性差异(P<0.05),与正常对照组无显著性差异。阴性对照组大鼠阴道外口可见浓稠的分泌物。动物扎堆、少动、竖毛,显微镜下见该组大鼠子宫炎症程度以及粘膜炎细胞数与正常对照组相比较,具有显著性差异。2.免疫组织化学方法检测大鼠宫颈中TNF-α的表达,正常组、阴性对照组、二黄散组吸光度值分别为0.1436±0.0027、0.1769±0.0035、0.1443±0.0012,阴性对照组较正常组明显升高(P<0.01)。二黄散组显著低于阴性对照组(P<0.01)。正常组、阴性对照组、二黄散组中IL-10的吸光度值分别为0.1336±0.0031、0.1386±0.0049、0.1547±0.0051。阴性对照组比正常组表达升高,二黄散组与阴性对照组相比其表达上升,差异具有显著性(P<0.01)。3.RT-PCR技术检测治疗后大鼠宫颈组织中TNF-αmRNA的表达,正常对照组、阴性对照组、二黄散组值分别为0.103±0.031,0.979±0.045,0.719±0.026,阴性对照组较正常对照组明显升高(P<0.01),二黄散组较阴性对照组下降(P<0.01)。IL-10mRNA在正常组、阴性对照组、二黄散组中分别为0.172±0.019、0.487±0.026、0.726±0.021,二黄散组较阴性对照组表达明显升高(P<0.01)。
结论:1.采用阴道苯酚胶浆注射可使大鼠宫颈发生炎症改变,其阴道分泌物增多,宫颈炎症程度及炎细胞数均较正常升高,符合宫颈炎症的表现,成功建立宫颈炎模型。2.二黄散能使宫颈病理形态学变化向正常转化。3.大鼠宫颈炎症发生后,宫颈局部TNF-α,IL-10均有升高。中药二黄散治疗可使TNF-α表达下降, IL-10表达升高,从而调节促炎因子和抗炎因子的平衡,有利于宫颈炎症的消散。
PartⅠThe clinical investigation on cervical disease of Wuhan
Objective To investigate the distribution of cervical disease of Wuhan to provide the clinical information for the research of the therapy and prevention of cervical disease.
Methods A total of 2634 patients in our hospital had been examined by TCT and TBS from December 2004 toMay 2005.The The abnormal cases which had been selected by TCT were detected by colposcopical pathological examination and Hybrid CaptureⅡHPV testing.
Results 493 ( 18.71% ) abnormal smears were found out of 2635 cases, in which atypical squamous cell of undetermined significance (ASCUS) 271cases (10.28% ),low grade squamous intraep ithelial lesion (LSIL) 94 cases ( 3.57% ),high grade squamous intraep ithelial lesion (HSIL) 14 cases (0.53% ) , squamous cell carcinoma 1 case (0.04% ) , adenocarcinoma endometrium 1 case (0104% ).CINⅠ,CINⅡ,CINⅢcases which were diagnosed by colposcopical pathological examination were 31.18% (53 /170 )、23.53% (40 /170 )、7.06% (12 /170 ).HPV infection which was detected by TCT were 105 cases (3.98% ).High risk HPV-positive cases which were detected by Hybrid CaptureⅡHPV testing were 74 cases.
Conclusion The disorder of cervical is the normal disease of women.The CIN and HPV infection are the dominant factors which damage the healthy of women.
PartⅡThe clinical observation of the effect of Chinese traditional medicine -ErHuangSan on high risk HPV infection CINⅠ,Ⅱand and the expression of IFN-γ,TNF-α, IL-4,IL-10
Objective To observe the clinical effect of ErHuangSan on high risk HPV infection CINⅠ,Ⅱand the expession of IFN-γ,TNF-α, IL-4,IL-10.
Methods 158 cases of high risk HPV infection patients with CINⅠ,Ⅱwere employed in the study for 3 months. 94 cases were treated by Er Huang San .30 cases were treated byα-2b interferon pessus as the positive control .34 cases were treated by nothing as the blank control.All the cases were detected by Hybrid Cap tureⅡHPV testing, colposcopical pathological examination before and after the treatment.The ELISA was employed to detect the expression of IFN-γ,TNF-αIL-4,IL-10 in Erhuangsan group before and after the administering of ErHuangSan.
Results The therapeutic efficacy of ErHuangSan andα-2b interferon pessus on high risk HPV infection were 75.6% and 73.3% respectively. The therapeutic efficacy on CINⅠ,Ⅱwere 72.4% and 73.3%。The The therapeutic efficacy of ErHuangSan andα-2b interferon pessus had no significant difference and better than the blank group obviously.After the treatment of ErHuangSan,the expression of IFN-γand TNF-αraised but the IL-4 and IL-10 deduced.
Conclusion ErHuangSan has the therapeutic efftect on the cervical intraepithelial neopasia. ErHuangSan can raise the expression of Th1 cytokine,so that the cellular immunity predominate to eliminate the virus.
PartⅢThe effect of Chinese traditional medicine-ErHuangSan on the morphopathology and the expression of TNF-α,IL-10 in cervical tissues of cervicitis rats
Objective To investigate the effective method to build an animal model of cervicitis for the fundamental and clinical research of cervicitis. To investigate the effect of ErHuangSan on the morphopathology and the expression of TNF-α,IL-10 in cervical tissues of cervicitis rats before and after the treatment of ErHuangSan.Preliminary investigate the effect of ErHuangSan on local immunologic function of cervical tissues of Wistar rats.
Methods The vagina of experimental Wistar rats were injected the 20% mucilage of phenol to build the cervicitis model,the cervicitis rats were divided randomly to three groups: negative control group, ErHuangSan group and XiaoMiShuan(positive control) group which were treated by blank mucilage ,ErHuangSan and XiaoMiShuan respectively.The rats never be treated were employed as the blank control.the manifestation and the vaginal secretion of rats were observed.The cervical slices were HE stained, the morphological change and the inflammation level were observed by microscope.3.The immunohistochemistry(S-P) and reverse transcription-polymerase chain raction(RT-PCR) were employed to detect the expression of TNF-α,IL-10 in cervical tissues.
Results The thickness vaginal secretion could be seen at the collar extension of vagina of the negative control group.The animals of negative control group massed, pilo-erection, Compared with the blank control group,the dgree of cervical inflammation and the quanity inflammatory cells of negative control group had the significant difference(P<0.05). Compared with the negative control group, morphopathology of cervical and the quanity of inflammatory cells of the ErHuangSan group and XiaoMiShuan group had the significant difference (P<0.05). there was no diffrence between the blank control group, ErHuangSan group and XiaoMiShuan group. The immunohistochemistry(s-p) and reverse transcription-polymerase chain raction(RT-PCR) were employed to detect the expression of TNF-α.The absorbency in blank control group,negative group and ErHuangSan group were 0.1436±0.0027、0.1769±0.0035、0.1443±0.0012.Compared with blank control group ,the expression of TNF-αin negative control group increased obviously(P<0.01). Compared with negative control group,the expression of TNF-αin ErHuangSan group reduced(P<0.01).The absorbency value of IL-10 in blank control group,negative control group and ErHuangSan group were 0.1336±0.0031、0.1386±0.0049、0.1547±0.0051.The expression of IL-10 in ErHuangSan group increased.there was significant difference between the ErHuangSan group and negative control group(P<0.01). Reverse transcription-polymerase chain raction(RT-PCR) was employed to detect the expression of TNF-αand IL-10.The expression of TNF-αmRNA in blank control group,negative control group and ErHuangSan medicine group were 0.103±0.031,0.979±0.045,0.719±0.026 respectivily Compared with blank control group ,the expression of TNF-αin negative control group increased obviously(P<0.01). Compared with negative control group,the expression of TNF-αin ErHuangSan group reduced(P<0.01).The expreesion of IL-10 were0.172±0.019、0.487±0.026、0.726±0.021,in blank control group,negative control group and ErHuangSan group. The expression of IL-10 in ErHuangSan group increased.there was significant difference between the ErHuangSan group and negative control group(P<0.01).
Conclusion: The injection of 20% phenol mucilage to the vagina of experiment rats can result in the inflammation of cervical . The ErHuangSan was conducive to the healing of the cervical. Along with the occurrence of cevititis ,the expression of cytokine TNF-αand IL-10 raised..The traditional Chinese traditional medicine-ErHuangSan can reduce the expression of TNF-αand raise the expression of IL-10 to adjust the immunity balance of cervical which is good for the convalescence of cervicitis.
目的了解武汉地区宫颈疾病的分布情况,为研究宫颈疾病的发病机制、诊治及预防提供临床资料。
方法对2004年12月至2005年5月在同济医院妇产科门诊就诊的2635例慢性宫颈炎患者行TCT检查和TBS细胞学分类诊断,对TCT检查发现异常的患者进行阴道镜病理检查和HC-ⅡHPV DNA检测。
结果2635例TCT涂片中检出异常涂片493例(18.71%) ,其中不典型鳞状细胞(ASCUS)271例(10.28%) ,低度鳞状上皮内病变(LSIL) 94例(3.57%) ,高度鳞状上皮内病变(HSIL) 14例( 0.53%),鳞状细胞癌(SCC) 1例(0.04% ) ,子宫内膜腺癌1例(0.04%)。阴道镜病检CINⅠ、CINⅡ、CINⅢ检出率分别为31.18% ( 53 /170 )、23.53% ( 40 /170 )、7.06% ( 12 /170 )。TCT示HPV感染共105例,行HPV-DNA检测其中高危型HPV阳性者74例,占70.48%。
结论宫颈疾病是育龄妇女的常见病,其中宫颈上皮不典型增生及高危型HPV感染是困扰女性生殖健康的主要元凶。
第二部分中药二黄散治疗CINⅠ,Ⅱ合并高危型HPV感染的临床观察及其对血清中IFN-γ,TNF-α,IL-4和IL-10的影响
目的:观察中药二黄散治疗CINⅠ,Ⅱ合并高危型HPV感染的临床疗效及其对血清中IFN-γ,TNF-α,IL-4和IL-10的影响。
方法:CINⅠ,Ⅱ合并高危型HPV感染158例,其中94例采用二黄散治疗3个月,30例采用α-2b干扰素栓进行对照治疗及34例空白对照,应用二代免疫杂交捕获技术(HC-Ⅱ)于治疗前后分别检查宫颈涂片中高危型HPV-DNA及阴道镜病理检查。抽取二黄散治疗组患者血液,用ELISA方法检测用中药二黄散治疗前后血液中IFN-γ,TNF-α,IL-4和IL-10变化情况。
结果:二黄散与α-2b干扰素栓对高危型HPV感染的治疗作用有效率分别为75.6%,73.3%。对于CINⅠ,Ⅱ的治疗有效率为72.4%及73.3%。二者作用相近但明显高于未用药治疗组。CINⅠ,Ⅱ合并高危型HPV感染患者用中药二黄散治疗后,IFN-γ,TNF-α升高而IL-4,IL-10下降。
结论:二黄散对于宫颈上皮内瘤变有一定治疗作用。二黄散能使高危型HPV感染者Th1类细胞因子升高,Th2类细胞因子降低,使细胞免疫占优势,从而有利于病毒的清除。
第三部分中药二黄散对大鼠子宫颈炎病理形态学的作用及对大鼠宫颈TNF-α,IL-10表达的影响
目的:探讨大鼠宫颈炎模型的建立方法,以有效建立宫颈炎模型,为基础及临床研究宫颈炎提供一种有用动物模型。评价中药二黄散对于大鼠宫颈炎病理形态学的作用,观察使用中药治疗前后大鼠宫颈局部TNF-α,IL-10表达的变化情况,初步探讨中药二黄散对大鼠宫颈免疫功能的影响作用。
方法:1.建立实验大鼠宫颈炎模型,将20%苯酚浆胶注入实验大鼠阴道内,1次/2日,共5次。2.造模成功后第2天,将造模组大鼠分3组,分别给予相当于成人用量30倍的二黄散,消糜栓(阳性对照)和空白基质(阴性对照),均隔日给药1次,共12次。此外,将未经任何处理的大鼠作为正常对照组。观察大鼠整体状况及阴道分泌物性状。治疗结束后次日处死动物,取子宫观察,宫颈常规石蜡切片行HE染色并在显微镜下观察宫颈形态学变化及炎症程度。3.分别采用免疫组织化学(S-P法),逆转录-聚合酶链反应(RT-PCR)检测中药二黄散用药前后大鼠宫颈TNF-α,IL-10蛋白和mRNA表达。
结果:1.病理检查结果:中药二黄散组和消糜栓组(阳性对照组)与阴性对照组相应部位比较,分泌物及炎症程度明显减轻,炎症细胞浸润明显减少,比较有显著性差异(P<0.05),与正常对照组无显著性差异。阴性对照组大鼠阴道外口可见浓稠的分泌物。动物扎堆、少动、竖毛,显微镜下见该组大鼠子宫炎症程度以及粘膜炎细胞数与正常对照组相比较,具有显著性差异。2.免疫组织化学方法检测大鼠宫颈中TNF-α的表达,正常组、阴性对照组、二黄散组吸光度值分别为0.1436±0.0027、0.1769±0.0035、0.1443±0.0012,阴性对照组较正常组明显升高(P<0.01)。二黄散组显著低于阴性对照组(P<0.01)。正常组、阴性对照组、二黄散组中IL-10的吸光度值分别为0.1336±0.0031、0.1386±0.0049、0.1547±0.0051。阴性对照组比正常组表达升高,二黄散组与阴性对照组相比其表达上升,差异具有显著性(P<0.01)。3.RT-PCR技术检测治疗后大鼠宫颈组织中TNF-αmRNA的表达,正常对照组、阴性对照组、二黄散组值分别为0.103±0.031,0.979±0.045,0.719±0.026,阴性对照组较正常对照组明显升高(P<0.01),二黄散组较阴性对照组下降(P<0.01)。IL-10mRNA在正常组、阴性对照组、二黄散组中分别为0.172±0.019、0.487±0.026、0.726±0.021,二黄散组较阴性对照组表达明显升高(P<0.01)。
结论:1.采用阴道苯酚胶浆注射可使大鼠宫颈发生炎症改变,其阴道分泌物增多,宫颈炎症程度及炎细胞数均较正常升高,符合宫颈炎症的表现,成功建立宫颈炎模型。2.二黄散能使宫颈病理形态学变化向正常转化。3.大鼠宫颈炎症发生后,宫颈局部TNF-α,IL-10均有升高。中药二黄散治疗可使TNF-α表达下降, IL-10表达升高,从而调节促炎因子和抗炎因子的平衡,有利于宫颈炎症的消散。
PartⅠThe clinical investigation on cervical disease of Wuhan
Objective To investigate the distribution of cervical disease of Wuhan to provide the clinical information for the research of the therapy and prevention of cervical disease.
Methods A total of 2634 patients in our hospital had been examined by TCT and TBS from December 2004 toMay 2005.The The abnormal cases which had been selected by TCT were detected by colposcopical pathological examination and Hybrid CaptureⅡHPV testing.
Results 493 ( 18.71% ) abnormal smears were found out of 2635 cases, in which atypical squamous cell of undetermined significance (ASCUS) 271cases (10.28% ),low grade squamous intraep ithelial lesion (LSIL) 94 cases ( 3.57% ),high grade squamous intraep ithelial lesion (HSIL) 14 cases (0.53% ) , squamous cell carcinoma 1 case (0.04% ) , adenocarcinoma endometrium 1 case (0104% ).CINⅠ,CINⅡ,CINⅢcases which were diagnosed by colposcopical pathological examination were 31.18% (53 /170 )、23.53% (40 /170 )、7.06% (12 /170 ).HPV infection which was detected by TCT were 105 cases (3.98% ).High risk HPV-positive cases which were detected by Hybrid CaptureⅡHPV testing were 74 cases.
Conclusion The disorder of cervical is the normal disease of women.The CIN and HPV infection are the dominant factors which damage the healthy of women.
PartⅡThe clinical observation of the effect of Chinese traditional medicine -ErHuangSan on high risk HPV infection CINⅠ,Ⅱand and the expression of IFN-γ,TNF-α, IL-4,IL-10
Objective To observe the clinical effect of ErHuangSan on high risk HPV infection CINⅠ,Ⅱand the expession of IFN-γ,TNF-α, IL-4,IL-10.
Methods 158 cases of high risk HPV infection patients with CINⅠ,Ⅱwere employed in the study for 3 months. 94 cases were treated by Er Huang San .30 cases were treated byα-2b interferon pessus as the positive control .34 cases were treated by nothing as the blank control.All the cases were detected by Hybrid Cap tureⅡHPV testing, colposcopical pathological examination before and after the treatment.The ELISA was employed to detect the expression of IFN-γ,TNF-αIL-4,IL-10 in Erhuangsan group before and after the administering of ErHuangSan.
Results The therapeutic efficacy of ErHuangSan andα-2b interferon pessus on high risk HPV infection were 75.6% and 73.3% respectively. The therapeutic efficacy on CINⅠ,Ⅱwere 72.4% and 73.3%。The The therapeutic efficacy of ErHuangSan andα-2b interferon pessus had no significant difference and better than the blank group obviously.After the treatment of ErHuangSan,the expression of IFN-γand TNF-αraised but the IL-4 and IL-10 deduced.
Conclusion ErHuangSan has the therapeutic efftect on the cervical intraepithelial neopasia. ErHuangSan can raise the expression of Th1 cytokine,so that the cellular immunity predominate to eliminate the virus.
PartⅢThe effect of Chinese traditional medicine-ErHuangSan on the morphopathology and the expression of TNF-α,IL-10 in cervical tissues of cervicitis rats
Objective To investigate the effective method to build an animal model of cervicitis for the fundamental and clinical research of cervicitis. To investigate the effect of ErHuangSan on the morphopathology and the expression of TNF-α,IL-10 in cervical tissues of cervicitis rats before and after the treatment of ErHuangSan.Preliminary investigate the effect of ErHuangSan on local immunologic function of cervical tissues of Wistar rats.
Methods The vagina of experimental Wistar rats were injected the 20% mucilage of phenol to build the cervicitis model,the cervicitis rats were divided randomly to three groups: negative control group, ErHuangSan group and XiaoMiShuan(positive control) group which were treated by blank mucilage ,ErHuangSan and XiaoMiShuan respectively.The rats never be treated were employed as the blank control.the manifestation and the vaginal secretion of rats were observed.The cervical slices were HE stained, the morphological change and the inflammation level were observed by microscope.3.The immunohistochemistry(S-P) and reverse transcription-polymerase chain raction(RT-PCR) were employed to detect the expression of TNF-α,IL-10 in cervical tissues.
Results The thickness vaginal secretion could be seen at the collar extension of vagina of the negative control group.The animals of negative control group massed, pilo-erection, Compared with the blank control group,the dgree of cervical inflammation and the quanity inflammatory cells of negative control group had the significant difference(P<0.05). Compared with the negative control group, morphopathology of cervical and the quanity of inflammatory cells of the ErHuangSan group and XiaoMiShuan group had the significant difference (P<0.05). there was no diffrence between the blank control group, ErHuangSan group and XiaoMiShuan group. The immunohistochemistry(s-p) and reverse transcription-polymerase chain raction(RT-PCR) were employed to detect the expression of TNF-α.The absorbency in blank control group,negative group and ErHuangSan group were 0.1436±0.0027、0.1769±0.0035、0.1443±0.0012.Compared with blank control group ,the expression of TNF-αin negative control group increased obviously(P<0.01). Compared with negative control group,the expression of TNF-αin ErHuangSan group reduced(P<0.01).The absorbency value of IL-10 in blank control group,negative control group and ErHuangSan group were 0.1336±0.0031、0.1386±0.0049、0.1547±0.0051.The expression of IL-10 in ErHuangSan group increased.there was significant difference between the ErHuangSan group and negative control group(P<0.01). Reverse transcription-polymerase chain raction(RT-PCR) was employed to detect the expression of TNF-αand IL-10.The expression of TNF-αmRNA in blank control group,negative control group and ErHuangSan medicine group were 0.103±0.031,0.979±0.045,0.719±0.026 respectivily Compared with blank control group ,the expression of TNF-αin negative control group increased obviously(P<0.01). Compared with negative control group,the expression of TNF-αin ErHuangSan group reduced(P<0.01).The expreesion of IL-10 were0.172±0.019、0.487±0.026、0.726±0.021,in blank control group,negative control group and ErHuangSan group. The expression of IL-10 in ErHuangSan group increased.there was significant difference between the ErHuangSan group and negative control group(P<0.01).
Conclusion: The injection of 20% phenol mucilage to the vagina of experiment rats can result in the inflammation of cervical . The ErHuangSan was conducive to the healing of the cervical. Along with the occurrence of cevititis ,the expression of cytokine TNF-αand IL-10 raised..The traditional Chinese traditional medicine-ErHuangSan can reduce the expression of TNF-αand raise the expression of IL-10 to adjust the immunity balance of cervical which is good for the convalescence of cervicitis.
引文
1. Del Amo J, Gonzalez C, Losana J, et al. Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain. Sex Transm Infect, 2005; 81(1): 79-84.
2.倪凤云,张梅月.子宫颈癌发病年轻化临床回顾性分析.实用诊断与治疗杂志, 2004; 18(4): 337-338
3. Kurman RJ,Solomon D.The Bethesda system for reporting cervical/vaginal cytologic diagnosis.New York:Walsworth publishing,1994,1-1.
4.康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察.时珍国医国药,1998,9(4):322-323.
5. Mosmann TR,Cherwinski H,Bond MW,et al.Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.J Immunol,1986, 136( 7):2348-2357.
6. Kharkevitch DD,Seito D,Balch GC,et al.Characterization of autologous tumor specific Thelper-cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Cancer,1994,58(3):317-323.
7. Al-Saleh W,Giannini SL,Jacobs N,et al.Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of theuterine cervix.Pathology,1998,184 (3):283-290.
8.徐林霞,武延隽. HPV感染者Th1/Th2细胞漂移情况研究.长治医学院学报,2002,16(1):7-8.
9. Tsukui T ,Hildesheim A ,Schiffman MH , et al . Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirusderived peptides:correlation with cervical pathology.Cancer Res,1996 ,56(17):3967-3974.
10. Lee BN,Follen M,Shen DY,et al.Depressed type 1 cytokine synthesis bysuperantigen-activated CD4+ T cells of women with human papillo-mavirus-related high-grade squamous intraepithelial lesions.Clin Diagn Lab Immunol,2004,11 (2):239-244.
11.章文华.子宫颈病变的诊治要点.人民卫生出版社,2006,第一版,29-33.
12. Nuovo J, Melnikow J, Howell LP. New tests for cervical cancer screening. Am Fam Physician, 2001, 64(5):729-73.
13. Wright TC Jr,et al.2001 cousensus guidelines for the management of women with cervical cytological abnormalities.JAMA 2002,287:2120-2129.
14.潘秦镜,李凌,乔友林,等.液基细胞学筛查宫颈癌的研究中华肿瘤学杂志,2001,23:309-311.
15.顾美皎. TBS系统中异常上皮细胞的诊断和处理.中国实用妇科与产科杂志, 2003,19(8):466-467.
16.马博文,郭云泉,马丽骊.液基薄层细胞技术对宫颈上皮细胞异常筛查作用的研究.中华病理学杂志, 2004,33(3):287-290.
17. Biscotti CV, Dawson AE, Dziura B, et al.Assisted primary screening using the automated ThinPrep Imaging System.Am J Clin Pathol,2005,123 (2):281-287.
18. Pan Q, Belinson JL, LiL, et al. A thin-layer, liquid-based paptest formass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study.Acta Cytol,2003,47(1):45-50.
19. Kulasingam SL, Hughes JP, KiviatNB, et al.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 2002, 288(14):1749-1757.
20.邹春芳,祖贻.AS2S2诱导腺癌细胞凋亡的实验研究.实用肿瘤杂志2004,9(6):507-510.
21.张晨.雄黄对肝癌细胞系BEL-7420增生的影响.肝脏.2004,9(2):112-113.
22.刘一波,朱文,詹云丽.雄黄洗剂体外抑菌作用考察.实用中西医结合临床,2002,2(2):49-50.
23.纪淑芳,张亚敏,谢福全,等.雄黄生品和酸奶飞炮制品的药效学比较.长春中医学院学报,2000,16(1):44-45.
24.王梦昌,郭桂丽,刘陕西,等.雄黄治疗慢性粒细胞性白血病7例疗效观察.陕西医学杂志,2002,31(2):152-153.
25.潘凤芝.单味雄黄外敷带状疱疹50例.中国中药基础医学杂志,2003,9(7):77.
26.王一波.纳米雄黄粉体药代动力学研究.解放军药学学报,2002,18(6):380.
27.黄兆胜.中药学.北京:人民卫生出版社,2002:212-214.
28.李永和.中西结合治疗重度宫颈糜烂50例临床观察.中华实用中西医杂志. 2003,3(16):565.
29. Kjaer SK, Chakerian B, van der Brule AJC, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity. Cancer Epidemiol Biomarkers Prev 2001;10:101–106.
30. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
31. Helmerhorst TJM, Meijer CJLM. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002;12:235–256.
32. Mu?oz N, Bosch FX, de SanjoséS, et al for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.
33. Moscicki A-B, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences by phylogenetic type. J Infect Dis 2004;190:37–45.
34. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20–25.
35. Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with humanpapillomavirus-associated neoplasms. J Natl Cancer Inst 1997;89:185–186.
36. Spellberg B, Edwards JE. Type1/type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76–102.
37. Clerici M, Shearer GM. The Th1–Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575–581.
38. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997;89:245–250.
39.兰进,杨世林,郑玉权,等.黄连的研究进展.中草药, 2001,32 (2) : 1139.
40.郝钰,邱全瑛等.小檗碱对淋巴细胞与血管内皮细胞粘附及粘附分子的影响.中国免疫学杂志, 1999, 15(11) : 523-525.
41.范英昌宋卓敏等.中药阴道泡腾片对实验性大鼠宫颈炎病理形态学影响的研究.中国实验方剂学杂志.1997,3(5):35-37.
42.乐杰.主编,妇产科学.第6版,北京:人民卫生出版社,2004:255-256.
43. Kulkani RN,Durge PM.Role of socio-economic factors and cytology in cervical erosion in reproductive age group women.India journal of medical sciences,2002,56(12):598-601.
44.王志启,王建六等.宫颈电熨术后并发宫颈囊肿一例。实用妇科与产科杂志, 2003,19(1):20.
1. Kharkevitch DD,Seito D,Balch GC,et al .Characterization of autologous tumor specific Thelper-cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma.Cancer,1994,58(3):317-323.
2. Qiu FB,Wu LQ,Lu Y.et al.Predominant expression of Th1-type cytokines in primary hepatic cancer and adjacent liver tissues.Hepatobiliary Pancreat Dis Int,2007,6(1):63-66.
3. osmann TR,Cherwinski H,Bond MW,et al.Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.J Immunol,1986,136 (7):2348-2357.
4. Firestein GS,Reoeder WD,Laxer JA,et al.A new murine CD4+ cell subset with an unrestricted cytokine profile.J Immunol 1989,143(2):518-25.
5. Groux H,O'Garra A,Bigler M,et al.A CD4+ T-cell subset inhibits antigen specific T-cell responses and prevents colitis.Nature,1997,389(6652):737-742.
6. Lappin MB,Campbell JD.The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy.Blood Rev, 2000,14(4):228-239.
7. Kawamura K,Bahar R,Natsume W,et al.Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther, 2002,9(1):109-115.
8. Rissoan MC,Soumelis V,Kadowaki N,et al.Reciprocal control of T helper cell and dendritic cell differentiation .Science,1999,283(5405):1183-1186.
9. Rayman P,Wesa AK,Richmond AL,et al.Effect of renal cell carcinomas on the development of type 1 T-cell responses.Clin Cancer Res, 2004,10(18 pt 2):6360S-6366S.
10. Sparano A,Lathers DM,Achille N,et al.Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cellcarcinoma.Otolaryngol Head Neck Surg, 2004,131(5):573-576.
11. Sandmand M,Bruunsgaard H,Kemp K,et al.Is ageing associated with a shift in the balance between Type1 and Type2 cytokines in humans.Clin Exp Immunol,2002,127(1):107-114.
12. Punnonen R,Teisala K,Kuoppala T,et al.Cytokine production profilesin the peritoneal fluids of patients with malignant or benign gynecologic tumors.Cancer,1998,83 (4):788-796.
13. Kusuda T,Shigemasa K,Arihiro K,et al.Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.Oncol Rep,2005,13(6):1153-1158.
14. Kjaer SK,Chakerian B,van den Brule AJ,et al.High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity(intercourse). Cancer Epidemiol Biomarkers Prev,2001,10(2):101–106.
15. Moscicki A-B,Ellenberg JH,Farhat S,et al.Persistence of human papillomavirus infection in HIV-infected and uninfected adolescent girls: risk factors and differences by phylogenetic type.J Infect Dis, 2004,190(1):37–45.
16. .Wu TC,Kurman RJ.Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Natl Cancer Inst,1997,89(3):185–187.
17.徐林霞,武延隽.HPV感染者Th1/Th2细胞漂移情况研究.长治医学院学报,2002 ,16(1) :7-8.
18. De Gruijl TD,Bontkes HJ.Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.Int J Cancer,1996 Dec 11,68(6):731-8.
19. Scott M,Stites DP,Moscicki AB.Th1 cytokine patterns in cervical human papillomavirus infection.Clin Diagn Lab Immunol ,1999,6(5):751-755.
20. Farzaneh F.Roberts S,Mandal D,et.al.The IL-10 -1082G polymorphism is associatedwith clearance of HPV infection.BJOG.,2006,13(8):961-964.
21. Sharma A,Rajappa M,Saxena A,et.al.Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix.Int J Gynecol Cancer. 2007 Mar 1; [Epub ahead of print]
22. Al-Saleh W,Giannini SL, Jacobs N,et al.Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervical. Pathology,1998,184(3):283-290.
23. Alcocer-Gongzalez JM,Berumen J,Tamez-Guerra R.et al.In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells.Viral Immunol,2006,19(3):481-491.
24. Tsukui T,Hildesheim A,Schiffman MH,et al.Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides:correlation with cervical pathology.Cancer Res,1996,56 (17):3967-3974.
25. Lee BN,Follen M,Shen DY,et al.Depressed type 1 cytokine synthesis by superantigen-activated CD4+ T cells of women with human papillomavirus-related high-grade squamous intraepithelial lesions[J].Clin Diagn Lab Immunol,2004,11 (2) :239-244.
26. Warrino DE,Olson WC,Knapp WT,et al.Disease-stage variance in functional CD4( + ) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.Clin Cancer Res,2004,10(10):3301-3308.
27. Pardo Govea T,Callejas D,Nunez Troconis J, et al.Gamma interferon (IFN-gamma) ,tumor necrosis factor alpha (TNF-alpha) and interleukins 2 ,4 and 6 ( IL-2 ,IL-4 ,IL-6) in cervical-uterine cells of intraepithelial neoplasia :a preliminary report.Invest Clin,2005,46(1):5-13.
28. Nguyen HH,Broker TR,Chow LT,et al.Immune responses to human papillomavirus in genital tract of women with cervical cancer.Gynecol Oncol,2005,96(2):452-461.
29. Kato M,Shinohara H,Goto S,et al.Clinical experience of EET therapy for 75 advancedcancer patients.Anticancer Res,1998,18(5D):3941-3949.
30. Peeva E,Fishman AD,Goddard G,et al.Rheumatoid arthritis exacerbation caused by exogenous interleukin-12.Arthritis Rheum,2000,43(2) :461-463.
31. Santin AD,Hermonat PL,Ravaqqi A,et al.Induction of human papillomavirus-specific CD4 ( + ) and CD8 ( + ) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer.J Virol, 1999, 73(7):5402-5410.
32. Chu NR,Wu HB,et al.Immunotherapy of a human papillomavirus (HPV) type 16E7-expressing tumour by administration of fusion protein comprisin mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16E7.Clin Exp Immunol ,2000,121(2):216-225.
33. Preville X,Ladant D,Timmerman B,et al.Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16E7 oncoprotein.Cancer Res,2005,65(2):614-619.
34. Pinto LA,Edwards J,Castle PE,et al.Cellular immune responses to human papillomavirus(HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.Infect Dis,2003,188(2):327-338.
35. De Jong A,vander Hulst JM,Kenter GG,et al..Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer.Cancer,2005,114(2):274-282.
1.江苏中医学院.中医大辞典(上册).第一版.上海:上海科学技术出版社,1986.2338.
2.中华人民共和国卫生部药典委员会.中华人民共和国药典.北京:人民卫生出版社,化学工业出版社,1990.275-276.
3.刘陕西主编.肿瘤调亡及分化的基础应用研究.第一版.西安:陕西科学技术出版社,2005.136.
4.田金改,吕扬,周俊国,等.矿物药雄黄及其伴生矿物的x-衍射图谱分析研究.药物分析杂志,1998,18(2):86-89.
5.梁国刚,张其伟.朱砂、雄黄中各成分的溶解度及其药效、毒副作用的影响.中国中药杂志,2002,27(5):391-392.
6.刘一波,朱文,詹云丽.雄黄洗剂体外抑菌作用考察.实用中西医结合临床,2002,2(2):49-50.
7.康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察.时珍国医国药,989(4):322-323.
8.白月辉,黄世林.雄黄对NB4、HL-60的促调亡作用.中华血液学杂志,998,9(9):477-480.
9.钟璐,芳源,韩洁英,等.和雄黄对白血病细胞PML基因及其表达蛋白的影响.上海第二医科大学学报,2001,21(2):106-109.
10.张晨,黄世林,向阳.低剂量雄黄诱导NB4细胞细胞调亡的研究.中国中医基础医学杂志,2000,6(2):81-82.
11.邹春芳,祖贻.AS2S2诱导腺癌细胞凋亡的实验研究.实用肿瘤杂志2004,9(6):507-510.
12.张晨.雄黄对肝癌细胞系BEL-7420增生的影响.肝脏.2004,9(2):112-113.
13.张晨,黄世林,向阳,等.硫化砷对K_562/ADM细胞HSP蛋白表达的影响.国癌症杂志,2001,1(1):3-34.
14.周霭祥,陈志伟,杨经敏,等.青黄散治疗慢性粒细胞性白血病86例临床观察.世界中西医结合大会论文摘要集,1997年.
15.陈思宇,刘陕西,李信民.雄黄对急性早幼粒细胞白血病细胞诱导调亡和促进分化的双重作用.西安交通大学学报(医学版),2002,23(4):401-404.
16. Deng Y,Xu H,Huang K.et al.Size effects of realga particles on apoptosis in a human umbilical veinendothelial cell line:ECV-304.Pharmacological Research, 2001, 44(6):513-518.
17.徐碧辉.雄黄抑制小鼠肉瘤S180的尺寸效应的初步研究.武汉大学学报(自然科学版),2000,46(3):288-290.
18.纪淑芳,张亚敏,谢福全,等.雄黄生品和酸奶飞炮制品的药效学比较.长春中医学院学报,2000,16(1):44-45.
19.孙恩亭,卜新柱,钱怡宁,等.中药雄黄的致突变性实验研究.中国中医基础医学杂志,1998 ,4(11) :52.
20.林有坤,郑文军,吴易,等.雄黄对狼疮鼠肾功能的近期影响.广西医科大学学报,2003,24(6):60.
21.高学熙,王信淇,马建军.雄黄治疗骨髓异常增生综合征14例.临床内科杂志,1998,15(3):125.
22.陆培道.口服雄黄治疗急性早幼粒细胞白血病(ANLL-M3)66例.中国实验诊断学,1998,(6):319.
23.王梦昌,郭桂丽,刘陕西,等.雄黄治疗慢性粒细胞性白血病7例疗效观察.陕西医学杂志,2002,31(2):152-153.
24.王梦昌,李信民,刘陕西,等.雄黄治疗维甲酸耐药急性早幼粒白血病M-3及诱导调亡的作用.西安医科大学学报,2002,23(2):175-177.
25.关键平,袁炜,杨浩,等.雄黄治疗维甲酸耐药急性早幼粒细胞白血病临床研究.陕西肿瘤医学,2002,10(4):281-282.
26.黄东胜.复方雄黄散外用治疗带状疱疹64例.浙江中医杂志,1993,28(8):365.
27.潘凤芝.单味雄黄外敷带状疱疹50例.中国中药基础医学杂志,2003,9(7):77.
28.李西文,田美香,刘霞.紫花地丁加雄黄外敷治疗流行性腮腺炎86例.中国民间疗法,2001,9(12):35.
29.丁晓辉,董爱红.细胞调亡与雄黄的临床应用.浙江中西医结合杂志,2000,10(5):318-319.
30.傅兰芳安玉梅.中药治疗宫颈糜烂的疗效观察.宁夏医学院学报,2000,22(3):221-222.
31.拉不登,杨晓春等.蒙西医结合治疗骨及关节结核50例临床观察.中国民族民间医药杂志,2000,(42) :22.
32.张扬.内服消坚丸外贴红膏治疗瘰疬58例.陕西医学,1997,18(5) :198.
33. Lee - Chen SF,Yu CT.Effect of arsenate on the DNA repair of UV-irradiated Chinese hamster ovary cell.Mutagenesis,1992,(7) :927.
34.多兰,黄月珍,沈大为,等.砷引起基底细胞癌的临床和病理特点.中国皮肤性病学杂志,1999,13(2):85-86.
35.李勇,朱惠刚,潘漪清.砷对大鼠的致畸作用.中华预防医学杂志,1998,32(1):37-39.
36.彭平建.应警惕雄黄制剂中砷的毒性.中医药信息,1996,(2) :21-22.
37.李巧如,任健康,刘宗智,等18种中草药抗菌作用的筛选.陕西中医,2002,23(6):555- 556.
38.匡铁吉,董梅,宋萍,等.黄连素对结核分枝杆菌的体外抑菌作用.中国中药杂志,2001, 26(12): 867 - 868.
39.陈国良,叶寿山,刘家骏,等.金地蓝消毒片对小鼠感染模型的体内抗菌作用观察.安徽医学,2002,23(5):5-7.
40. LEE D U,KANG Y J.Effects of 13-alkyl-substituted Berberine Alkaloids on the Exp ression of COX2Ⅱ, TNF-α,iNOS and IL-12 Production in LPS-stimulated Macrophages.Life Sciences,2003,73(3):1401-1412.
41.刘志峰,李桂生,傅风华,等.8种中药注射剂体外抗内毒素作用的观察.中草药,2002,33(1):58 - 59.
42.姜庆城,王彦美,陈同刚,等.双黄连注射液在生物体内抗细菌内毒素的效果观察.中国医院药学杂志,2002,22(5):276-278.
43.李凡,易世红,赵春艳,等.双黄连粉针剂抗病毒作用.中草药,2002,33(1):52-55.
44. Mantena SK,Sharma SD,Kativar SK.Berberine,a natural product induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.Mol Cancer Ther,2006,5(2):296-308.
45. Letasiova S,Jantova S,Miko M,et al.Effect of berberine on proliferation ,biosynthesis of macromolecules ,cell cycle and induction of intercalation with DNA ,dsDNA damage and apoptosis in ehrlich ascites carcinoma cells.J Pharm Pharmacol,2006,58(2):263-270.
46. Lin JP,Yang JS,Lee JH,et al.Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line.World J Gastroenterol,2006,12(1):21-28.
47. Iizuka N ,Miyamoto K, Okita K ,et al .Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines.Cancer Lett,2000,148(1):19-25.
48. Li XK,Motwani M,Tong W,et al.Huanglian,A chinese herbal extract,inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells.Mol Pharmacol,2000,58(6):1287-1293.
49. Iizuka N,Hazama S,Yoshimura K,et al.Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma.I nt J Cancer,2002,99(2):286-291.
50. Anis KV,Rajeshkumar NV,Kuttan R.Inhibition of chemical carcinogenesis by Berberine in rats and mice.Pharm Pharmacol,2001,53 (5):763-768.
51.娄金丽,邱全瑛,林洪生,等.小檗碱对人胃癌细胞增殖、细胞周期及CD44v6表达的影响.中国免疫学杂志,2004,20:315-317.
52. Joo M ,Lee HK ,Kang YK.Expression of E-cadherin ,beta-caterin ,CD44s and CD44v6 in gastric adenocarcinoma:relationship with lymphnode metastasis.Anticancer Res,2003,23 (2B):1581.
53.陈淑珍,江敏,甄永苏.HERG钾通道表达与小檗碱的抗肿瘤作用的关系.中国天然药物,2005,3(1):48.
54.何贤辉,曾耀英,徐丽慧,等.黄连素对T淋巴细胞活化和增殖的抑制作用.中国病理生理杂志,2002,18(10):1183-1186.
55. Manrinova E K,Nikolovad B,Popovad N,et al.Suppression of Experimental Antoimmune Tubulointerstitia Nephritis in BALB/C mice by Berberine. Immunopharmacology, 2000,48(12):9-16.
56.付晓春,王敏伟.黄连解毒汤的抗血栓作用研究.沈阳药科大学学报,2001,18(6):425-427.
57.王睿,顾月荣.黄连降糖胶囊与二甲双胍治疗对2型糖尿病疗效比较.中医药学刊,2003, 21( 7):1189–1190.
58.刘长山,王秀军.黄连素对醛糖还原酶活性的抑制及防治糖尿病神经病变的临床意义.中国中药杂志,2002,27(12):950-952.
59.康巧真,叶菲,杨顺裕.黄连素治疗充血性心力衰竭17例疗效观察.中国自然医学杂志,2002,4(2):83-84.
60.曹国扬.心先安联合黄连素治疗病态窦房结综合征43例临床观察.中西医结合心脑血管病杂志,2003,1(3):171-172.
61.郑凌云,周祖玉,陶大昌,等.黄连素对缺血再灌注心肌细胞损伤的保护作用.四川大学学报(医学版),2003,34(3):452-454.
62.徐静华,于庆海,蔡爽,等.黄连解毒汤对小鼠急性脑缺血、缺氧的影响.沈阳药科大学学报,2003,2(3):132-134.
63.李运伦.黄连清降合剂对自发性高血压大鼠影响的实验研究.山东中医杂志,2002,21 (7):421-425.
64.李运伦.黄连清降合剂治疗原发性高血压46例临床研究.中医杂志,2003,44(3):199-201.
65.张德付.双黄连粉针剂静脉注射致异常反应3例.中医研究,2001,14(5):58-59.
66.朱惠平.双黄连注射液与硫酸庆大霉素注射液存在配伍禁忌.中国民间疗法,2003,11 (10):45-46.
67.张佳思,向国春.黄连粉针剂在临床应用中配伍禁忌的观察.中国局解手术学杂志,2001,10(4):411-412.
68.李信民等.瑞尔康主要成分雄黄的动物急性毒性试验.现代中医,2001,1(1):43
69. Hughes MF.Arsenic toxicity and potential mechanisms of action.Toxicol.Lett,2002,133(1):1-16
2.倪凤云,张梅月.子宫颈癌发病年轻化临床回顾性分析.实用诊断与治疗杂志, 2004; 18(4): 337-338
3. Kurman RJ,Solomon D.The Bethesda system for reporting cervical/vaginal cytologic diagnosis.New York:Walsworth publishing,1994,1-1.
4.康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察.时珍国医国药,1998,9(4):322-323.
5. Mosmann TR,Cherwinski H,Bond MW,et al.Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.J Immunol,1986, 136( 7):2348-2357.
6. Kharkevitch DD,Seito D,Balch GC,et al.Characterization of autologous tumor specific Thelper-cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Cancer,1994,58(3):317-323.
7. Al-Saleh W,Giannini SL,Jacobs N,et al.Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of theuterine cervix.Pathology,1998,184 (3):283-290.
8.徐林霞,武延隽. HPV感染者Th1/Th2细胞漂移情况研究.长治医学院学报,2002,16(1):7-8.
9. Tsukui T ,Hildesheim A ,Schiffman MH , et al . Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirusderived peptides:correlation with cervical pathology.Cancer Res,1996 ,56(17):3967-3974.
10. Lee BN,Follen M,Shen DY,et al.Depressed type 1 cytokine synthesis bysuperantigen-activated CD4+ T cells of women with human papillo-mavirus-related high-grade squamous intraepithelial lesions.Clin Diagn Lab Immunol,2004,11 (2):239-244.
11.章文华.子宫颈病变的诊治要点.人民卫生出版社,2006,第一版,29-33.
12. Nuovo J, Melnikow J, Howell LP. New tests for cervical cancer screening. Am Fam Physician, 2001, 64(5):729-73.
13. Wright TC Jr,et al.2001 cousensus guidelines for the management of women with cervical cytological abnormalities.JAMA 2002,287:2120-2129.
14.潘秦镜,李凌,乔友林,等.液基细胞学筛查宫颈癌的研究中华肿瘤学杂志,2001,23:309-311.
15.顾美皎. TBS系统中异常上皮细胞的诊断和处理.中国实用妇科与产科杂志, 2003,19(8):466-467.
16.马博文,郭云泉,马丽骊.液基薄层细胞技术对宫颈上皮细胞异常筛查作用的研究.中华病理学杂志, 2004,33(3):287-290.
17. Biscotti CV, Dawson AE, Dziura B, et al.Assisted primary screening using the automated ThinPrep Imaging System.Am J Clin Pathol,2005,123 (2):281-287.
18. Pan Q, Belinson JL, LiL, et al. A thin-layer, liquid-based paptest formass screening in an area of China with a high incidence of cervical carcinoma: a cross-sectional, comparative study.Acta Cytol,2003,47(1):45-50.
19. Kulasingam SL, Hughes JP, KiviatNB, et al.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 2002, 288(14):1749-1757.
20.邹春芳,祖贻.AS2S2诱导腺癌细胞凋亡的实验研究.实用肿瘤杂志2004,9(6):507-510.
21.张晨.雄黄对肝癌细胞系BEL-7420增生的影响.肝脏.2004,9(2):112-113.
22.刘一波,朱文,詹云丽.雄黄洗剂体外抑菌作用考察.实用中西医结合临床,2002,2(2):49-50.
23.纪淑芳,张亚敏,谢福全,等.雄黄生品和酸奶飞炮制品的药效学比较.长春中医学院学报,2000,16(1):44-45.
24.王梦昌,郭桂丽,刘陕西,等.雄黄治疗慢性粒细胞性白血病7例疗效观察.陕西医学杂志,2002,31(2):152-153.
25.潘凤芝.单味雄黄外敷带状疱疹50例.中国中药基础医学杂志,2003,9(7):77.
26.王一波.纳米雄黄粉体药代动力学研究.解放军药学学报,2002,18(6):380.
27.黄兆胜.中药学.北京:人民卫生出版社,2002:212-214.
28.李永和.中西结合治疗重度宫颈糜烂50例临床观察.中华实用中西医杂志. 2003,3(16):565.
29. Kjaer SK, Chakerian B, van der Brule AJC, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity. Cancer Epidemiol Biomarkers Prev 2001;10:101–106.
30. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12–19.
31. Helmerhorst TJM, Meijer CJLM. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002;12:235–256.
32. Mu?oz N, Bosch FX, de SanjoséS, et al for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.
33. Moscicki A-B, Ellenberg JH, Farhat S, et al. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences by phylogenetic type. J Infect Dis 2004;190:37–45.
34. Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999;354:20–25.
35. Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with humanpapillomavirus-associated neoplasms. J Natl Cancer Inst 1997;89:185–186.
36. Spellberg B, Edwards JE. Type1/type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76–102.
37. Clerici M, Shearer GM. The Th1–Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575–581.
38. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997;89:245–250.
39.兰进,杨世林,郑玉权,等.黄连的研究进展.中草药, 2001,32 (2) : 1139.
40.郝钰,邱全瑛等.小檗碱对淋巴细胞与血管内皮细胞粘附及粘附分子的影响.中国免疫学杂志, 1999, 15(11) : 523-525.
41.范英昌宋卓敏等.中药阴道泡腾片对实验性大鼠宫颈炎病理形态学影响的研究.中国实验方剂学杂志.1997,3(5):35-37.
42.乐杰.主编,妇产科学.第6版,北京:人民卫生出版社,2004:255-256.
43. Kulkani RN,Durge PM.Role of socio-economic factors and cytology in cervical erosion in reproductive age group women.India journal of medical sciences,2002,56(12):598-601.
44.王志启,王建六等.宫颈电熨术后并发宫颈囊肿一例。实用妇科与产科杂志, 2003,19(1):20.
1. Kharkevitch DD,Seito D,Balch GC,et al .Characterization of autologous tumor specific Thelper-cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma.Cancer,1994,58(3):317-323.
2. Qiu FB,Wu LQ,Lu Y.et al.Predominant expression of Th1-type cytokines in primary hepatic cancer and adjacent liver tissues.Hepatobiliary Pancreat Dis Int,2007,6(1):63-66.
3. osmann TR,Cherwinski H,Bond MW,et al.Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.J Immunol,1986,136 (7):2348-2357.
4. Firestein GS,Reoeder WD,Laxer JA,et al.A new murine CD4+ cell subset with an unrestricted cytokine profile.J Immunol 1989,143(2):518-25.
5. Groux H,O'Garra A,Bigler M,et al.A CD4+ T-cell subset inhibits antigen specific T-cell responses and prevents colitis.Nature,1997,389(6652):737-742.
6. Lappin MB,Campbell JD.The Th1-Th2 classification of cellular immune responses: concepts, current thinking and applications in haematological malignancy.Blood Rev, 2000,14(4):228-239.
7. Kawamura K,Bahar R,Natsume W,et al.Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors. Cancer Gene Ther, 2002,9(1):109-115.
8. Rissoan MC,Soumelis V,Kadowaki N,et al.Reciprocal control of T helper cell and dendritic cell differentiation .Science,1999,283(5405):1183-1186.
9. Rayman P,Wesa AK,Richmond AL,et al.Effect of renal cell carcinomas on the development of type 1 T-cell responses.Clin Cancer Res, 2004,10(18 pt 2):6360S-6366S.
10. Sparano A,Lathers DM,Achille N,et al.Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cellcarcinoma.Otolaryngol Head Neck Surg, 2004,131(5):573-576.
11. Sandmand M,Bruunsgaard H,Kemp K,et al.Is ageing associated with a shift in the balance between Type1 and Type2 cytokines in humans.Clin Exp Immunol,2002,127(1):107-114.
12. Punnonen R,Teisala K,Kuoppala T,et al.Cytokine production profilesin the peritoneal fluids of patients with malignant or benign gynecologic tumors.Cancer,1998,83 (4):788-796.
13. Kusuda T,Shigemasa K,Arihiro K,et al.Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.Oncol Rep,2005,13(6):1153-1158.
14. Kjaer SK,Chakerian B,van den Brule AJ,et al.High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity(intercourse). Cancer Epidemiol Biomarkers Prev,2001,10(2):101–106.
15. Moscicki A-B,Ellenberg JH,Farhat S,et al.Persistence of human papillomavirus infection in HIV-infected and uninfected adolescent girls: risk factors and differences by phylogenetic type.J Infect Dis, 2004,190(1):37–45.
16. .Wu TC,Kurman RJ.Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J Natl Cancer Inst,1997,89(3):185–187.
17.徐林霞,武延隽.HPV感染者Th1/Th2细胞漂移情况研究.长治医学院学报,2002 ,16(1) :7-8.
18. De Gruijl TD,Bontkes HJ.Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.Int J Cancer,1996 Dec 11,68(6):731-8.
19. Scott M,Stites DP,Moscicki AB.Th1 cytokine patterns in cervical human papillomavirus infection.Clin Diagn Lab Immunol ,1999,6(5):751-755.
20. Farzaneh F.Roberts S,Mandal D,et.al.The IL-10 -1082G polymorphism is associatedwith clearance of HPV infection.BJOG.,2006,13(8):961-964.
21. Sharma A,Rajappa M,Saxena A,et.al.Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix.Int J Gynecol Cancer. 2007 Mar 1; [Epub ahead of print]
22. Al-Saleh W,Giannini SL, Jacobs N,et al.Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervical. Pathology,1998,184(3):283-290.
23. Alcocer-Gongzalez JM,Berumen J,Tamez-Guerra R.et al.In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells.Viral Immunol,2006,19(3):481-491.
24. Tsukui T,Hildesheim A,Schiffman MH,et al.Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides:correlation with cervical pathology.Cancer Res,1996,56 (17):3967-3974.
25. Lee BN,Follen M,Shen DY,et al.Depressed type 1 cytokine synthesis by superantigen-activated CD4+ T cells of women with human papillomavirus-related high-grade squamous intraepithelial lesions[J].Clin Diagn Lab Immunol,2004,11 (2) :239-244.
26. Warrino DE,Olson WC,Knapp WT,et al.Disease-stage variance in functional CD4( + ) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.Clin Cancer Res,2004,10(10):3301-3308.
27. Pardo Govea T,Callejas D,Nunez Troconis J, et al.Gamma interferon (IFN-gamma) ,tumor necrosis factor alpha (TNF-alpha) and interleukins 2 ,4 and 6 ( IL-2 ,IL-4 ,IL-6) in cervical-uterine cells of intraepithelial neoplasia :a preliminary report.Invest Clin,2005,46(1):5-13.
28. Nguyen HH,Broker TR,Chow LT,et al.Immune responses to human papillomavirus in genital tract of women with cervical cancer.Gynecol Oncol,2005,96(2):452-461.
29. Kato M,Shinohara H,Goto S,et al.Clinical experience of EET therapy for 75 advancedcancer patients.Anticancer Res,1998,18(5D):3941-3949.
30. Peeva E,Fishman AD,Goddard G,et al.Rheumatoid arthritis exacerbation caused by exogenous interleukin-12.Arthritis Rheum,2000,43(2) :461-463.
31. Santin AD,Hermonat PL,Ravaqqi A,et al.Induction of human papillomavirus-specific CD4 ( + ) and CD8 ( + ) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer.J Virol, 1999, 73(7):5402-5410.
32. Chu NR,Wu HB,et al.Immunotherapy of a human papillomavirus (HPV) type 16E7-expressing tumour by administration of fusion protein comprisin mycobacterium bovis bacilli Calmette-Guerin (BCG) hsp65 and HPV16E7.Clin Exp Immunol ,2000,121(2):216-225.
33. Preville X,Ladant D,Timmerman B,et al.Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16E7 oncoprotein.Cancer Res,2005,65(2):614-619.
34. Pinto LA,Edwards J,Castle PE,et al.Cellular immune responses to human papillomavirus(HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.Infect Dis,2003,188(2):327-338.
35. De Jong A,vander Hulst JM,Kenter GG,et al..Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer.Cancer,2005,114(2):274-282.
1.江苏中医学院.中医大辞典(上册).第一版.上海:上海科学技术出版社,1986.2338.
2.中华人民共和国卫生部药典委员会.中华人民共和国药典.北京:人民卫生出版社,化学工业出版社,1990.275-276.
3.刘陕西主编.肿瘤调亡及分化的基础应用研究.第一版.西安:陕西科学技术出版社,2005.136.
4.田金改,吕扬,周俊国,等.矿物药雄黄及其伴生矿物的x-衍射图谱分析研究.药物分析杂志,1998,18(2):86-89.
5.梁国刚,张其伟.朱砂、雄黄中各成分的溶解度及其药效、毒副作用的影响.中国中药杂志,2002,27(5):391-392.
6.刘一波,朱文,詹云丽.雄黄洗剂体外抑菌作用考察.实用中西医结合临床,2002,2(2):49-50.
7.康永,李先荣,程霞,等.雄黄药理作用的实验研究及其毒性观察.时珍国医国药,989(4):322-323.
8.白月辉,黄世林.雄黄对NB4、HL-60的促调亡作用.中华血液学杂志,998,9(9):477-480.
9.钟璐,芳源,韩洁英,等.和雄黄对白血病细胞PML基因及其表达蛋白的影响.上海第二医科大学学报,2001,21(2):106-109.
10.张晨,黄世林,向阳.低剂量雄黄诱导NB4细胞细胞调亡的研究.中国中医基础医学杂志,2000,6(2):81-82.
11.邹春芳,祖贻.AS2S2诱导腺癌细胞凋亡的实验研究.实用肿瘤杂志2004,9(6):507-510.
12.张晨.雄黄对肝癌细胞系BEL-7420增生的影响.肝脏.2004,9(2):112-113.
13.张晨,黄世林,向阳,等.硫化砷对K_562/ADM细胞HSP蛋白表达的影响.国癌症杂志,2001,1(1):3-34.
14.周霭祥,陈志伟,杨经敏,等.青黄散治疗慢性粒细胞性白血病86例临床观察.世界中西医结合大会论文摘要集,1997年.
15.陈思宇,刘陕西,李信民.雄黄对急性早幼粒细胞白血病细胞诱导调亡和促进分化的双重作用.西安交通大学学报(医学版),2002,23(4):401-404.
16. Deng Y,Xu H,Huang K.et al.Size effects of realga particles on apoptosis in a human umbilical veinendothelial cell line:ECV-304.Pharmacological Research, 2001, 44(6):513-518.
17.徐碧辉.雄黄抑制小鼠肉瘤S180的尺寸效应的初步研究.武汉大学学报(自然科学版),2000,46(3):288-290.
18.纪淑芳,张亚敏,谢福全,等.雄黄生品和酸奶飞炮制品的药效学比较.长春中医学院学报,2000,16(1):44-45.
19.孙恩亭,卜新柱,钱怡宁,等.中药雄黄的致突变性实验研究.中国中医基础医学杂志,1998 ,4(11) :52.
20.林有坤,郑文军,吴易,等.雄黄对狼疮鼠肾功能的近期影响.广西医科大学学报,2003,24(6):60.
21.高学熙,王信淇,马建军.雄黄治疗骨髓异常增生综合征14例.临床内科杂志,1998,15(3):125.
22.陆培道.口服雄黄治疗急性早幼粒细胞白血病(ANLL-M3)66例.中国实验诊断学,1998,(6):319.
23.王梦昌,郭桂丽,刘陕西,等.雄黄治疗慢性粒细胞性白血病7例疗效观察.陕西医学杂志,2002,31(2):152-153.
24.王梦昌,李信民,刘陕西,等.雄黄治疗维甲酸耐药急性早幼粒白血病M-3及诱导调亡的作用.西安医科大学学报,2002,23(2):175-177.
25.关键平,袁炜,杨浩,等.雄黄治疗维甲酸耐药急性早幼粒细胞白血病临床研究.陕西肿瘤医学,2002,10(4):281-282.
26.黄东胜.复方雄黄散外用治疗带状疱疹64例.浙江中医杂志,1993,28(8):365.
27.潘凤芝.单味雄黄外敷带状疱疹50例.中国中药基础医学杂志,2003,9(7):77.
28.李西文,田美香,刘霞.紫花地丁加雄黄外敷治疗流行性腮腺炎86例.中国民间疗法,2001,9(12):35.
29.丁晓辉,董爱红.细胞调亡与雄黄的临床应用.浙江中西医结合杂志,2000,10(5):318-319.
30.傅兰芳安玉梅.中药治疗宫颈糜烂的疗效观察.宁夏医学院学报,2000,22(3):221-222.
31.拉不登,杨晓春等.蒙西医结合治疗骨及关节结核50例临床观察.中国民族民间医药杂志,2000,(42) :22.
32.张扬.内服消坚丸外贴红膏治疗瘰疬58例.陕西医学,1997,18(5) :198.
33. Lee - Chen SF,Yu CT.Effect of arsenate on the DNA repair of UV-irradiated Chinese hamster ovary cell.Mutagenesis,1992,(7) :927.
34.多兰,黄月珍,沈大为,等.砷引起基底细胞癌的临床和病理特点.中国皮肤性病学杂志,1999,13(2):85-86.
35.李勇,朱惠刚,潘漪清.砷对大鼠的致畸作用.中华预防医学杂志,1998,32(1):37-39.
36.彭平建.应警惕雄黄制剂中砷的毒性.中医药信息,1996,(2) :21-22.
37.李巧如,任健康,刘宗智,等18种中草药抗菌作用的筛选.陕西中医,2002,23(6):555- 556.
38.匡铁吉,董梅,宋萍,等.黄连素对结核分枝杆菌的体外抑菌作用.中国中药杂志,2001, 26(12): 867 - 868.
39.陈国良,叶寿山,刘家骏,等.金地蓝消毒片对小鼠感染模型的体内抗菌作用观察.安徽医学,2002,23(5):5-7.
40. LEE D U,KANG Y J.Effects of 13-alkyl-substituted Berberine Alkaloids on the Exp ression of COX2Ⅱ, TNF-α,iNOS and IL-12 Production in LPS-stimulated Macrophages.Life Sciences,2003,73(3):1401-1412.
41.刘志峰,李桂生,傅风华,等.8种中药注射剂体外抗内毒素作用的观察.中草药,2002,33(1):58 - 59.
42.姜庆城,王彦美,陈同刚,等.双黄连注射液在生物体内抗细菌内毒素的效果观察.中国医院药学杂志,2002,22(5):276-278.
43.李凡,易世红,赵春艳,等.双黄连粉针剂抗病毒作用.中草药,2002,33(1):52-55.
44. Mantena SK,Sharma SD,Kativar SK.Berberine,a natural product induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.Mol Cancer Ther,2006,5(2):296-308.
45. Letasiova S,Jantova S,Miko M,et al.Effect of berberine on proliferation ,biosynthesis of macromolecules ,cell cycle and induction of intercalation with DNA ,dsDNA damage and apoptosis in ehrlich ascites carcinoma cells.J Pharm Pharmacol,2006,58(2):263-270.
46. Lin JP,Yang JS,Lee JH,et al.Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line.World J Gastroenterol,2006,12(1):21-28.
47. Iizuka N ,Miyamoto K, Okita K ,et al .Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines.Cancer Lett,2000,148(1):19-25.
48. Li XK,Motwani M,Tong W,et al.Huanglian,A chinese herbal extract,inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells.Mol Pharmacol,2000,58(6):1287-1293.
49. Iizuka N,Hazama S,Yoshimura K,et al.Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma.I nt J Cancer,2002,99(2):286-291.
50. Anis KV,Rajeshkumar NV,Kuttan R.Inhibition of chemical carcinogenesis by Berberine in rats and mice.Pharm Pharmacol,2001,53 (5):763-768.
51.娄金丽,邱全瑛,林洪生,等.小檗碱对人胃癌细胞增殖、细胞周期及CD44v6表达的影响.中国免疫学杂志,2004,20:315-317.
52. Joo M ,Lee HK ,Kang YK.Expression of E-cadherin ,beta-caterin ,CD44s and CD44v6 in gastric adenocarcinoma:relationship with lymphnode metastasis.Anticancer Res,2003,23 (2B):1581.
53.陈淑珍,江敏,甄永苏.HERG钾通道表达与小檗碱的抗肿瘤作用的关系.中国天然药物,2005,3(1):48.
54.何贤辉,曾耀英,徐丽慧,等.黄连素对T淋巴细胞活化和增殖的抑制作用.中国病理生理杂志,2002,18(10):1183-1186.
55. Manrinova E K,Nikolovad B,Popovad N,et al.Suppression of Experimental Antoimmune Tubulointerstitia Nephritis in BALB/C mice by Berberine. Immunopharmacology, 2000,48(12):9-16.
56.付晓春,王敏伟.黄连解毒汤的抗血栓作用研究.沈阳药科大学学报,2001,18(6):425-427.
57.王睿,顾月荣.黄连降糖胶囊与二甲双胍治疗对2型糖尿病疗效比较.中医药学刊,2003, 21( 7):1189–1190.
58.刘长山,王秀军.黄连素对醛糖还原酶活性的抑制及防治糖尿病神经病变的临床意义.中国中药杂志,2002,27(12):950-952.
59.康巧真,叶菲,杨顺裕.黄连素治疗充血性心力衰竭17例疗效观察.中国自然医学杂志,2002,4(2):83-84.
60.曹国扬.心先安联合黄连素治疗病态窦房结综合征43例临床观察.中西医结合心脑血管病杂志,2003,1(3):171-172.
61.郑凌云,周祖玉,陶大昌,等.黄连素对缺血再灌注心肌细胞损伤的保护作用.四川大学学报(医学版),2003,34(3):452-454.
62.徐静华,于庆海,蔡爽,等.黄连解毒汤对小鼠急性脑缺血、缺氧的影响.沈阳药科大学学报,2003,2(3):132-134.
63.李运伦.黄连清降合剂对自发性高血压大鼠影响的实验研究.山东中医杂志,2002,21 (7):421-425.
64.李运伦.黄连清降合剂治疗原发性高血压46例临床研究.中医杂志,2003,44(3):199-201.
65.张德付.双黄连粉针剂静脉注射致异常反应3例.中医研究,2001,14(5):58-59.
66.朱惠平.双黄连注射液与硫酸庆大霉素注射液存在配伍禁忌.中国民间疗法,2003,11 (10):45-46.
67.张佳思,向国春.黄连粉针剂在临床应用中配伍禁忌的观察.中国局解手术学杂志,2001,10(4):411-412.
68.李信民等.瑞尔康主要成分雄黄的动物急性毒性试验.现代中医,2001,1(1):43
69. Hughes MF.Arsenic toxicity and potential mechanisms of action.Toxicol.Lett,2002,133(1):1-16